Efficacy and Tolerability of the Histrelin Implant (VANTAS®)

Introduction: Androgen deprivation is the cornerstone in management of patients with advanced or metastatic prostate cancer. Androgen deprivation can be achieved in a number of different ways, all, leading to lowering of testosterone to castrate range. We present our initial experience with a newly introduced oneyear formulation. Material and Methods: Consecutive patients managed with Histrelin implants. Main out-come, testosterone levels 3 and 12 months following implantation. Results: Histrelin implants maintained testosterone levels within castration range in all patients 3 and 12 months following implantation. Major side effects were the expected consequences of androgen deprivation, only few patients had complaints related to the implant or procedure. Conclusion: Histrelin implants may serve as a valid alternative in patients undergoing either permanent or short-term androgen deprivation therapy